Grafa News and Videos — Page 160

Gorilla Technology Group (NASDAQ:GRRR) signed a non-binding letter of intent to acquire its first U.S. data center, with completion targeted by the end of November 2026.

Sagimet Biosciences (NASDAQ:SGMT) reported 52-week denifanstat acne results from license partner Ascletis’ Phase 3 extension study, including 57% Investigator’s Global Assessment success.

Profound Medical (NASDAQ:PROF) entered a co-education agreement with Telix Pharmaceuticals to support physician education on imaging-informed prostate care.

Arcutis Biotherapeutics (NASDAQ:ARQT) presented new ZORYVE clinical data in infants with atopic dermatitis and patients with psoriasis at EADV and Fall Clinical.

Teva Pharmaceutical Industries (NYSE:TEVA) received U.S. Food and Drug Administration approval for WELTRUZA, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia.

Valion Bio (NASDAQ:VBIO) and Shear Kershman Laboratories completed formulation work on an oral mucosal version of Entolimod for potential use in radiation emergencies.

Glaukos (NYSE:GKOS) reported positive topline Phase 4 results showing iDose TR plus cataract surgery reduced mean diurnal intraocular pressure by 11.1 mmHg from baseline at Month 3.

Seaport Therapeutics (NASDAQ:SPTX) presented Phase 1 GlyphAgo data showing a statistically significant 6.8-fold increase in agomelatine bioavailability compared with unmodified agomelatine.

SpaceX (NASDAQ:SPCX) announced an agreement to acquire a nationwide low-band spectrum license portfolio, sending T-Mobile (NASDAQ:TMUS), AT&T (NYSE:T) and Verizon (NYSE:VZ) lower in premarket trading.

MINISO Group (NYSE:MNSO) reported preliminary mainland China gross merchandise value growth of 25%–30% year over year for the third quarter of 2026.